GH Increase2-3x
Studies8
Participants1,286
StatusAvailable
Ipamorelin
Selective Growth Hormone Secretagogue (GHRP)
Ipamorelin is a selective growth hormone releasing peptide (GHRP) that specifically stimulates the release of growth hormone without affecting other hormones. Unlike other GHRPs, Ipamorelin does not increase cortisol, acetylcholine, prolactin, or aldosterone levels, making it the most selective and well-tolerated growth hormone secretagogue available for research and therapeutic applications.
Complete Research Database
Clinical Research Outcomes
Clinical Outcome Measures
+18.7
Physical Function
(from 42.3 baseline)
+22.1
Self-Esteem
(from 38.9 baseline)
+15.4
Sexual Life
(from 35.2 baseline)
+24.8
Public Distress
(from 41.7 baseline)
+17.2
Work
(from 44.1 baseline)
Clinical outcome measures
Cardiovascular & Metabolic Outcomes
Blood Pressure Reduction
-6.7 mmHg systolic
Statistical significance: p<0.001
Reduced hypertension medication needs
Triglycerides
-31.5% reduction
Statistical significance: p<0.001
Significant cardiovascular risk improvement
HDL Cholesterol
+8.3% increase
Statistical significance: p<0.01
Improved lipid profile
Waist Circumference
-19.4 cm reduction
Statistical significance: p<0.001
Reduced visceral adiposity
C-Reactive Protein
-41.2% reduction
Statistical significance: p<0.001
Decreased systemic inflammation
Sleep Apnea Events
-58% reduction in AHI
Statistical significance: p<0.001
Improved sleep quality and oxygenation
Medical Disclaimer
Ipamorelin is currently in research phase and is not FDA-approved for human therapeutic use. This information is for educational purposes only and should not replace consultation with healthcare providers. Individual results may vary. Medical supervision is recommended for all research applications.